| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (NCT04198766) | Inhibrx Biosciences, Inc | 2019-12-10 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations (NCT04161391) | Turning Point Therapeutics, Inc. | 2019-12-06 |
| The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC (NCT04193007) | Second Affiliated Hospital of Nanchang University | 2019-12-01 |
| A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation (NCT04165031) | Eli Lilly and Company | 2019-11-28 |
| Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer (NCT04187768) | Indiana University | 2019-11-26 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (NCT03965468) | ETOP IBCSG Partners Foundation | 2019-11-19 |
| A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients (NCT03390686) | Prestige Biopharma Limited | 2019-11-15 |
| Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC (NCT05277844) | Tata Memorial Hospital | 2019-11-11 |
| Cancer Genome Atlas of China:Lung Cancer (NCT04266483) | Xuanwu Hospital, Beijing | 2019-11-08 |
| Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (NCT04180371) | BicycleTx Limited | 2019-11-07 |
| This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (NCT03968419) | Novartis Pharmaceuticals | 2019-11-05 |
| Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers (NCT06255197) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-11-04 |
| Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers (NCT05800418) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-11-04 |
| Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer (NCT04153799) | Sun Yat-sen University | 2019-11-01 |
| Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC (NCT04133337) | Sichuan Cancer Hospital and Research Institute | 2019-11-01 |
| Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis (NCT04148898) | Second Affiliated Hospital of Nanchang University | 2019-11-01 |
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (NCT04036682) | Cullinan Therapeutics Inc. | 2019-10-31 |
| Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation (NCT04137718) | Shanghai Pulmonary Hospital, Shanghai, China | 2019-10-25 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study (NCT04676412) | Merck Sharp & Dohme LLC | 2019-10-23 |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer (NCT03908671) | Stemirna Therapeutics | 2019-10-18 |
| Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (NCT04165330) | Sarcoma Oncology Research Center, LLC | 2019-10-17 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (NCT04068896) | NGM Biopharmaceuticals, Inc | 2019-10-16 |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (NCT04069936) | WindMIL Therapeutics | 2019-10-15 |
| A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC (NCT04108013) | Xuanwu Hospital, Beijing | 2019-10-08 |
| Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation (NCT04063462) | Tianjin Medical University Cancer Institute and Hospital | 2019-10-01 |
| SBRT/RT in Oligometastatic Stage IV NSCLC (NCT05647590) | University Hospital Ostrava | 2019-10-01 |
| Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) (NCT04124731) | Shanghai Chest Hospital | 2019-10-01 |
| A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors (NCT04045496) | Jacobio Pharmaceuticals Co., Ltd. | 2019-09-26 |
| A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) (NCT03940703) | EMD Serono Research & Development Institute, Inc. | 2019-09-19 |
| Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer (NCT03853187) | Radboud University Medical Center | 2019-09-19 |
| Study to Evaluate the Safety of Nanoxel M Inj. (NCT04066335) | Samyang Biopharmaceuticals Corporation | 2019-09-18 |
| LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT04027946) | National Cancer Institute (NCI) | 2019-09-11 |
| Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (NCT03970746) | PDC*line Pharma SAS | 2019-09-10 |
| Study of KN046 With Chemotherapy in First Line Advanced NSCLC (NCT04054531) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-09-04 |
| A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) (NCT04022876) | Aileron Therapeutics, Inc. | 2019-09-03 |
| Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC (NCT05060796) | Second Affiliated Hospital of Guangzhou Medical University | 2019-09-01 |
| PDR001 + Panobinostat for Melanoma and NSCLC (NCT03982134) | Muhammad Furqan | 2019-09-01 |
| Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC (NCT03818776) | Case Comprehensive Cancer Center | 2019-08-30 |
| Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC (NCT03991403) | Samsung Medical Center | 2019-08-27 |
| MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer (NCT04078269) | University Hospital, Ghent | 2019-08-26 |
| Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC (NCT04087473) | National Cancer Centre, Singapore | 2019-08-23 |
| High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer (NCT03870529) | Wake Forest University Health Sciences | 2019-08-19 |
| Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy. (NCT04722406) | Sun Yat-sen University | 2019-08-15 |
| A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer (NCT03735680) | OncoNano Medicine, Inc. | 2019-08-09 |
| A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China (NCT04015778) | Guangdong Association of Clinical Trials | 2019-08-08 |
| Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (NCT04131543) | University of Bologna | 2019-08-07 |
| Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer (NCT03871153) | Greg Durm, MD | 2019-08-02 |
| Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer (NCT04304248) | Hao Long | 2019-08-01 |
| Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate (NCT04059874) | First Affiliated Hospital of Zhejiang University | 2019-07-31 |
| Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M (NCT04029350) | Tianjin Medical University Cancer Institute and Hospital | 2019-07-31 |
| A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC (NCT04167774) | Sun Yat-sen University | 2019-07-30 |
| First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation (NCT04006301) | Janssen Research & Development, LLC | 2019-07-26 |
| Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT03909334) | Xiuning Le | 2019-07-25 |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients (NCT03916627) | Regeneron Pharmaceuticals | 2019-07-23 |
| Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer (NCT03999710) | Memorial Sloan Kettering Cancer Center | 2019-07-19 |
| A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (NCT03953235) | Gritstone bio, Inc. | 2019-07-18 |
| Evaluation of NSCLC Patients' Oxygen Uptake On-kinetics at Cycle-ergometer During Prehabilitation (NCT04041297) | ADIR Association | 2019-07-16 |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) (NCT03974022) | Dizal Pharmaceuticals | 2019-07-09 |
| A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT03922997) | Hoffmann-La Roche | 2019-07-03 |
| A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (NCT04035486) | AstraZeneca | 2019-07-02 |
| Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit (NCT05348187) | QIAGEN Gaithersburg, Inc | 2019-07-01 |
| Circulating DNA in Surgically Treated NSCLC (NCT04037150) | Helsinki University Central Hospital | 2019-07-01 |
| First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NCT06521034) | Yongchang Zhang | 2019-06-27 |
| Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease (NCT03656627) | Alliance Foundation Trials, LLC. | 2019-06-27 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (NCT03944772) | AstraZeneca | 2019-06-25 |
| Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma (NCT04490564) | Pharmassist Ltd | 2019-06-25 |
| Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) (NCT03924869) | Merck Sharp & Dohme LLC | 2019-06-25 |
| AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies. (NCT04145232) | Ardigen | 2019-06-13 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） (NCT03910127) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-11 |
| Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (NCT03689855) | Washington University School of Medicine | 2019-06-05 |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer (NCT03915951) | Pfizer | 2019-06-04 |
| Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience (NCT03724331) | University of Nebraska | 2019-06-04 |
| Personalized DC Vaccine for Postoperative Cancer (NCT04147078) | Sichuan University | 2019-06-01 |
| Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC (NCT03987867) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer (NCT02480634) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2019-06-01 |
| A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC (NCT04840290) | Tang-Du Hospital | 2019-06-01 |
| Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT04632758) | Qilu Pharmaceutical Co., Ltd. | 2019-06-01 |
| Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours (NCT03852823) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-05-23 |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade (NCT03474497) | Megan Daly, MD | 2019-05-20 |
| Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC (NCT05637580) | Guangdong Provincial People's Hospital | 2019-05-20 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488) | Compass Therapeutics | 2019-05-17 |
| Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer (NCT03958097) | The First Hospital of Jilin University | 2019-05-17 |
| Crizotinib in ALK Rearranged Non-small-cell Lung Cancer (NCT04317651) | Fondazione Ricerca Traslazionale | 2019-05-16 |
| Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (NCT03836066) | Fundación GECP | 2019-05-15 |
| NADIM II: Neo-Adjuvant Immunotherapy (NCT03838159) | Fundación GECP | 2019-05-15 |
| Effect of Two Different Preoperative Training Densities in Patients With Non-small-cell Lung Cancer Before Lung Resection Surgery (NCT03936764) | ADIR Association | 2019-05-07 |
| Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (NCT03976518) | Gruppo Oncologico Italiano di Ricerca Clinica | 2019-05-07 |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (NCT03645928) | Iovance Biotherapeutics, Inc. | 2019-05-07 |
| Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI (NCT03924050) | Shanghai Junshi Bioscience Co., Ltd. | 2019-05-06 |
| The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial (NCT03859349) | St. Joseph's Healthcare Hamilton | 2019-05-06 |
| CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility (NCT03986463) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-05-01 |
| Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer (NCT03166254) | Washington University School of Medicine | 2019-04-30 |
| Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer (NCT04213170) | Sun Yat-sen University | 2019-04-29 |
| M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (NCT03840902) | EMD Serono Research & Development Institute, Inc. | 2019-04-16 |
| Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy (NCT03951012) | Muhammad Furqan | 2019-04-15 |
| Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (NCT03927573) | AvenCell Europe GmbH | 2019-04-15 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852) | TCR2 Therapeutics | 2019-04-15 |
| Multiplex Analysis of Circulating Tumor DNA (NCT03301961) | Peking University People's Hospital | 2019-04-11 |